Skip to main content
PRENW logo

Prenetics Global Limited (PRENW) Stock Price & Analysis

Prenetics Global Limited (PRENW) — price $0.0052 (-8.77%), as of the Nov 19, 2026 trading session.

Educational signal · not a buy or sell recommendation · How to read this

$0.0052 −$0.0005 (-8.77%)

Prenetics Global Limited · PRENW

Prenetics Global Limited is an investment holding company specializing in diagnostics and genetic testing, offering solutions like CircleDNA, Circle HealthPod, and ColoClear. The company focuses on preventative healthcare and early disease detection, operating primarily from its headquarters in Hong Kong.

Price as of Nov 19, 2026

Key Statistics

Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • PG · The Procter & Gamble Company · 88 /100
  • UL · Unilever PLC · 88 /100
  • CL · Colgate-Palmolive Company · 93 /100

See all scored stocks →

Price & valuation

As of
MeasureValue
Latest provided price$0.0052
Change on the day-8.77%
52-week range$0.0052 – $0.03
Shares traded on the day16.9K

Price & events

Other perspectives

Council score for Prenetics Global (PRENW): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Sep 3, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Strong
ROE Negative
Gross Margin Moderate

Read on: May 2, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On May 2, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Prenetics Global (PRENW), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Prenetics Global Limited (PRENW) is the company analyzed here. It employs 98 people and is led by Sheng Wu Yeung. In Q2 FY2026 it reported revenue of $46M and net income of -$9M.

2 · Latest results

What do the latest results show for Prenetics Global (PRENW)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $46M. Against analyst estimates the company has EPS beat 3 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$46M-$9M-$0.52 (diluted)
Q1 FY2026$36M-$23M-$1.36 (diluted)
Q4 FY2025$37M-$28M-$1.75 (diluted)
Q3 FY2025$24M-$7M-$0.53 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Prenetics Global (PRENW)?

Short answer · as of

The distress and quality screens read Altman Z 3.77 · Piotroski F 4. Trailing ratios: ROE -49.2% · ROA -44.0% · current ratio 4.04 · earnings yield -23.5% · free-cash-flow yield -12.1%.

Data-derived red flags

  • Negative return on equity (-49.2%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held PRENW in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported PRENW in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Common Questions About PRENW

These answers are editorial: 1 of these 1 answer is drawn from the PRENW research dossier (written Jun 15, 2026 by gemini-2.5-flash). Figures in this section are not part of the source register.

What is Prenetics Global Limited's strategy for growth in the preventative healthcare market?

Prenetics Global Limited's growth strategy in the preventative healthcare market is centered on its diverse portfolio of accessible diagnostic and genetic testing solutions.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 13 figures on this page — 7 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.